Neutrophil-to-lymphocyte Ratio as a Predictor of Malignancy of Intraductal Papillary Mucinous Neoplasms

Anticancer Res. 2021 Mar;41(3):1663-1669. doi: 10.21873/anticanres.14929.

Abstract

Background: Intraductal papillary mucinous neoplasm (IPMN) can lead, via the adenoma-carcinoma sequence, to invasive adenocarcinoma, which has a poor prognosis. Most IPMNs do not meet the indications for surgery and instead are monitored regularly, but no biomarkers of malignant transformation during surveillance have been established.

Patients and methods: A total of 50 patients with IPMN who underwent pancreatectomy were evaluated retrospectively. Clinicopathological parameters during the surveillance period before surgery were assessed to explore biomarkers for predicting malignancy.

Results: The serum level of carbohydrate antigen 19-9 was significantly higher in IPMN-derived invasive adenocarcinoma. The neutrophil-to-lymphocyte ratio was significantly lower in low-grade IPMN than high-grade and Inv-IPMN cases by univariate and multivariate analysis. Disease-free survival was significantly shorter in patients with high-grade and invasive IPMN compared with those with low-grade IPMN. In patients whose preoperative surveillance was performed for more than 12 months, the neutrophil-to-lymphocyte ratio was significantly higher in those with high-grade and invasive IPMNs compared with patients with low-grade IPMN in the year before surgery.

Conclusion: The NLR is a useful biomarker for distinguishing between low-grade and high-grade IPMN and thus should be monitored during surveillance.

Keywords: Neutrophil-to-lymphocyte ratio; adenocarcinoma; intraductal papillary mucinous neoplasm; surveillance.

MeSH terms

  • Aged
  • Biomarkers, Tumor
  • Female
  • Humans
  • Lymphocytes*
  • Male
  • Neoplasm Grading
  • Neutrophils*
  • Pancreatic Intraductal Neoplasms / immunology
  • Pancreatic Intraductal Neoplasms / mortality
  • Pancreatic Intraductal Neoplasms / pathology*
  • Pancreatic Intraductal Neoplasms / surgery
  • Pancreatic Neoplasms / immunology
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / pathology*
  • Pancreatic Neoplasms / surgery
  • Retrospective Studies

Substances

  • Biomarkers, Tumor